超导管中枢替换系统:一个新的双组件平台
Michail Penteris1, Konstantinos Lampropoulos2
1Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
概括
超导管的HighLife关置换系统为高风险患者的严重关吐提供了一种新的治疗方法. 早期的研究表明,高成功率和减少反,扩大了以前无法治疗的病例的选择.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 医疗器械技术 医疗器械技术
背景情况:
- 严重的额叶吐 (MR) 是常见的,并且往往未得到充分治疗,特别是在不适合进行手术或跨导管边缘到边缘修复 (M-TEER) 的患者中.
- 现有的过导管中枢置换 (TMVR) 选择在患者选择和输送方法方面存在局限性.
研究的目的:
- 评估HighLife跨导管中枢置换系统 (TMVR) 的可行性和早期结果.
- 评估HighLifeTMVR系统的安全性,有效性和程序性质,用于重度额头回的患者.
主要方法:
- 该HighLife系统采用了由两个组件组成的设计 (子环和自我扩展的生物假体),通过关动脉和横静脉接入传递.
- 分析了首次在人体和可行性研究中的早期临床数据,重点关注技术成功,MR减少和临床结果.
主要成果:
- 在早期的研究中,技术上的成功率很高.
- 观察到额头管的显著减少和短期到中期的良好的临床结果.
- 设备代已经扩大了对更广泛的解剖学的适用性,解决了诸如大圆环大小和LVOT阻塞等局限性.
结论:
- 高生活TMVR系统在高风险患者治疗严重的额头肌吐时显示出有前途的早期结果.
- 该系统的独特设计允许在不需要环状化或跨接入的情况下进行环形定.
- 进一步的临床试验是必要的,以确认长期的安全性,耐用性和疗效,可能建立HighLife作为一个可行的TMVR选项.
相关概念视频
Mitral Stenosis III: Medical Management
21
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
21
Mitral Regurgitation III: Medical Management
30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30
Mitral Valve Prolapse II: Assessment and Management
39
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
39
Mitral Stenosis I: Introduction
35
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
35
Mitral Valve Prolapse I: Introduction
43
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
43
Mitral Regurgitation I: Introduction
55
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
55


